摘要
Chemotherapy in combination with immune checkpoint inhibitor (ICI) or bevacizumab has demonstrated a superior effect for non-squamous non-small cell lung cancer (NS-NSCLC). There are still few randomized controlled trials (RCTs) investigating the differences between ICI plus chemotherapy (ICI-chemotherapy) and bevacizumab plus chemotherapy (Bev-chemotherapy) in first-line treatment of NS-NSCLC. We identified RCTs in databases and conference abstracts presented at international conferences by Sep 1, 2021. Bayesian network meta-analysis was performed using randomized effect consistency model to estimate hazard ratio (HR) and odds ratio (OR). The outcomes included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and grade >= 3 treatment-related adverse events (TRAEs). Fifteen RCTs (17 articles) of 6561 advanced NS-NSCLC patients receiving ICI-chemotherapy, Bev-chemotherapy, or chemotherapy at first-line were eligible for analysis. NMA results showed that first-line ICI-chemotherapy prolonged OS (HR 0.79, 0.66-0.94) in patients with advanced NS-NSCLC compared with Bev-chemotherapy, while no differences were in PFS, ORR, and grade >= 3 TRAEs (p > 0.05). Ranking plots suggested that ICI-chemotherapy had the most probability to offer the best OS (probability 0.993), PFS (probability 0.658), and ORR (probability 0.565), and Bev-chemotherapy had the most risks of grade >= 3 TRAEs (probability 0.833). Therefore, our findings showed that first-line ICI-chemotherapy was associated with better OS than Bev-chemotherapy in patients with advanced NS-NSCLC, and more clinical trials are warranted to confirm these results.
学科与关键词
- Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysisFu, Wenfan; Xu, Manman; Shi, Xingyuan; Jiang, Zeyong; Jian, Zhao; Lu, Dai*Therapeutic Advances in Chronic Disease, 2023, 14: 20406223231189224.
- Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysisLi, Huijuan; Han, Hedong; Li, Chuling; Wu, Ranpu; Wang, Zhaofeng; Wang, Yimin; Zhan, Ping; Lv, Tangfeng; Zhang, Fang; Song, Yong*; Liu, Hongbing*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231189430.被引 1
- Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trialBorghaeit, H.*; O'Byrnet, K. J.; Paz-Ares, L.; Ciuleanu, T. -E; Yu, X.; Pluzanski, A.; Nagrial, A.; Havel, L.; Kowalyszyn, R. D.; Valette, C. A.; Brahmer, J. R.; Reck, M.; Ramalingam, S. S.; Zhang, L.; Ntambwe, I.; Rabindran, S. K.; Nathan, F. E.; Balli, D.; Wu, Y. -L.ESMO Open, 2023, 8(6): 102065.
